Research programme: anti-inflammatory therapeutics - Mestag Therapeutics/Merck
Latest Information Update: 25 Oct 2024
At a glance
- Originator Mestag Therapeutics
- Developer Merck AG; Mestag Therapeutics
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Fibroblast modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation